WE ARE LEADER IN HERBAL EXTRACTS MARKET SINCE 2012
Â
About KINTAI
KINTAI Biotech Inc. is one of the major manufacturers of herbal extracts and pharmaceutical intermediate in China, and has been serving global health industry customers in the past 10 years.
KINTAI offers more than just manufacturing services, we offer our customers complete professional solutions, including product concept, selling points, testing, formulation, packaging, customs clearance, regulatory compliance, etc.
KINTAI is established by a high qualified team, owns the 12,000㎡ GMP workshop, 600㎡ R&D platform, 23 well-trained factory workers, 7 professional R&D and quality control people. We are experts in R&D, manufacturing and quality assurance.
KINTAI's leading products are Lappaconitine Bbr, Mangiferin, Dihydromyricetin, Dihydroquercetin, Polydatin, Rosmarinic acid, Chlorogenic acid, betulin, sanguinarine, Macleaya cordata extract, Centella asiatica extract and epimedium extract, etc.
Our health natural products have been sold well in more than thirty countries, including Europe, North America, Australia, Southeast Asia, Russia, etc., and are widely used in medicine, health food, cosmetics, food drinks, animal feed and other fields.
Â
Certification
KINTAI's products have successively passed the quality system and product certification such as FDA registration, ISO9001 certification, HACCP certification, Kosher certification, Halal certification, export food production enterprise filing, as well as a number of national invention patents and American invention patents for product technology.
The company has got more than 16 existing technical patents, including: efficient separation and purification technology, efficient sterilization and drying technology, membrane reaction separation and filtration technology, lappaconitine hydrobromide, dihydromyricetin, mangiferin, betulin and other technical invention patents.
Vision, Mission And Values
Vision of KINTAI
To be the leading company in development, manufacturing and distribution of active and nutraceutical ingredients in the pharmaceutical and nutritional sectors.
Providing quality products while complying with the highest levels of professional standards and responsibility.
Mission of KINTAI
Create value for our global customers by our strong R&D and Quality Assurance ability.
Contribute to Human health by our professional knowledge and services in developing cost effective,safe and potency natural products.
Values of KINTAI
Quality first, technology leading and innovation oriented to be leading biotechnology.
Being rigorous, realistic, customer first, and trustworthy to create a healthy life for human.
Development History
-
Founded in 2012
Xi'an Kintai Biotech Inc. was established.
-
Settled in 2014
Marketing Center was located in Xi'an Beilin Dahua Nanmen Center.
-
Qualification certification in 2016
The company has passed KOF-KOSHER and HALAL certification.
-
The laboratory was established in 2017
The plant extract laboratory was established in Xi’an aerospace base.
-
Preliminary development in 2018
The key technology of the company's high-purity rosmarinic acid has made a major breakthrough, which will greatly reduce the production cost and maximize the product value and customer benefits.
-
Sustainable development in 2019
The production base project in Xi'an Aerospace was put into use, and the annual quantity of refined and processed plant / herbal materials exceeded 200 tons/year for the first time.
-
High speed development in 2020
The Functional Components Extraction and Separation R&D Center project was successfully launched in Xi'an Airport Industrial Port of Zhongnan Hi tech, and the construction began in March 2020;
The key technologies of the company's core products, such as high-purity dihydromyricetin, betulin and betulinic acid, have made breakthroughs and applied for national invention patents.
-
Patent application in 2021
Kintai Airport Industrial Port High Purity Plantation Project has passed the environmental assessment approval and acceptance;
Mangiferin, the core product of the company, has successfully applied for the national invention patent and obtained the authorization, and the mangiferin is in the process of applying for the US invention patent.
-
New Journey in 2022
Kintai has passed the national high-tech enterprise certification;
The construction of 100000 level clean workshop has been completed and passed the acceptance;
Shaanxi Kintai Healthtech Inc. a sister company of Kintai Biotech Inc, was established and settled in the Sales Center of Zhongnan Hi tech Airport Industrial Port.
Â
Products
Enterprise data through authenticate